BR112013024828A2 - "derivados de sulfamida tendo um grupo adamantil e seu sal farmaceuticamente aceitável, agente inibitório a 11?-hsd1, e composição farmacêutica". - Google Patents
"derivados de sulfamida tendo um grupo adamantil e seu sal farmaceuticamente aceitável, agente inibitório a 11?-hsd1, e composição farmacêutica".Info
- Publication number
- BR112013024828A2 BR112013024828A2 BR112013024828A BR112013024828A BR112013024828A2 BR 112013024828 A2 BR112013024828 A2 BR 112013024828A2 BR 112013024828 A BR112013024828 A BR 112013024828A BR 112013024828 A BR112013024828 A BR 112013024828A BR 112013024828 A2 BR112013024828 A2 BR 112013024828A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- adamantyl group
- pharmaceutical composition
- inhibitory agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C07C311/59—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/04—Diamides of sulfuric acids
- C07C307/10—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
derivado de sulfamida tendo um grupo adamantil e seu sal farmaceuticamente aceitável a presente invenção refere-se a um derivado de sulfamida tendo um grupo adamantil representado pela fórmula 1 a seguir, ou um sal farmaceuticamente aceitável deste. o derivado de sulfamida suprime a atividade de deidrogenase 11<225>-hidróxi esteroide tipo 1 (11<225>-hsd1), e é últil no tratamento de várias doenças que são mediadas por 11<225>-hsd1 fórmula química 1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0029829 | 2011-03-31 | ||
KR20110029829 | 2011-03-31 | ||
KR10-2012-004235 | 2012-01-13 | ||
KR1020120004235A KR101332805B1 (ko) | 2011-03-31 | 2012-01-13 | 아다만틸기를 갖는 설파마이드 유도체 및 이의 약제학적으로 허용 가능한 염 |
PCT/KR2012/002407 WO2012134233A2 (ko) | 2011-03-31 | 2012-03-30 | 아다만틸기를 갖는 설파마이드 유도체 및 이의 약제학적으로 허용 가능한 염 |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013024828A2 true BR112013024828A2 (pt) | 2016-12-20 |
BR112013024828B1 BR112013024828B1 (pt) | 2020-08-04 |
Family
ID=47282486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013024828-9A BR112013024828B1 (pt) | 2011-03-31 | 2012-03-30 | Derivados de sulfamida tendo um grupo adamantil e seu sal farmaceuticamente aceitável, agente inibitório a 11b-hsd1, e composição farmacêutica |
Country Status (8)
Country | Link |
---|---|
US (1) | US9073906B2 (pt) |
EP (1) | EP2740723B1 (pt) |
JP (1) | JP5944483B2 (pt) |
KR (1) | KR101332805B1 (pt) |
CN (1) | CN104080766B (pt) |
BR (1) | BR112013024828B1 (pt) |
ES (1) | ES2633863T3 (pt) |
WO (1) | WO2012134233A2 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201608710TA (en) * | 2014-04-28 | 2016-11-29 | Jiangsu Kanion Parmaceutical Co Ltd | Anti-enterovirus 71 thiadiazolidine derivative |
WO2015165340A1 (zh) * | 2014-04-28 | 2015-11-05 | 南京明德新药研发股份有限公司 | 抗肠病毒71噻二唑烷衍生物 |
KR20220058826A (ko) * | 2020-10-29 | 2022-05-10 | 주식회사 피노바이오 | 시신경 보호 대상인 환자에게 점안제로 투여하기 위한 약학 조성물 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4368683B2 (ja) | 2002-02-01 | 2009-11-18 | メルク エンド カムパニー インコーポレーテッド | 糖尿病、肥満症および脂質代謝異常の治療に有用な11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ1阻害剤 |
US20040014422A1 (en) | 2002-07-19 | 2004-01-22 | Nokia Corporation | Method and system for handovers using service description data |
AU2003269242A1 (en) | 2002-10-11 | 2004-05-04 | Astrazeneca Ab | 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors |
US20060058315A1 (en) * | 2002-11-07 | 2006-03-16 | Astrazeneca Ab | 2-Oxo-ethanesulfonamide derivates |
TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
DE602004027171D1 (de) | 2003-04-11 | 2010-06-24 | High Point Pharmaceuticals Llc | Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase |
EP1615647B1 (en) | 2003-04-11 | 2010-01-20 | High Point Pharmaceuticals, LLC | Pharmaceutical use of fused 1,2,4-triazoles |
US20050245534A1 (en) | 2004-04-29 | 2005-11-03 | Link James T | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
WO2005108359A1 (en) | 2004-05-06 | 2005-11-17 | Pfizer Inc. | Novel compounds of proline and morpholine derivatives |
EP1747198B1 (en) | 2004-05-07 | 2008-06-04 | Janssen Pharmaceutica N.V. | Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
EP1794120B1 (en) | 2004-07-23 | 2012-04-11 | Nuada, LLC | Peptidase inhibitors |
UA87328C2 (en) * | 2004-08-30 | 2009-07-10 | Янссен Фармацевтика Н.В. | N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
BRPI0606256A2 (pt) | 2005-01-05 | 2009-06-09 | Abbott Lab | inibidores da enzima 11-beta-hidroxiesteróide desidrogenase tipo i, uso e composição farmacêutica compreendendo os mesmos |
KR20080076916A (ko) * | 2005-11-01 | 2008-08-20 | 트랜스테크 파르마, 인크. | 치환된 아미드의 약학적 사용 |
CN101351209A (zh) * | 2005-11-01 | 2009-01-21 | 转化技术制药公司 | 取代的酰胺的药学应用 |
WO2007057768A2 (en) * | 2005-11-18 | 2007-05-24 | Pfizer Products Inc. | Sulfonyl derivatives |
AU2006316087B2 (en) * | 2005-11-21 | 2011-03-10 | Shionogi & Co., Ltd. | Heterocyclic compound having inhibitory activity on 11-beta-hydroxysteroid dehydrogenase type I |
EP1801098A1 (en) | 2005-12-16 | 2007-06-27 | Merck Sante | 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors |
JP2007197369A (ja) | 2006-01-26 | 2007-08-09 | Sankyo Co Ltd | ベンゾチアジン誘導体 |
WO2008006702A1 (en) * | 2006-07-13 | 2008-01-17 | High Point Pharmaceuticals, Llc. | 11beta-hydroxysteroid dehydrogenase type 1 active compounds |
US8927715B2 (en) * | 2006-08-25 | 2015-01-06 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 |
JP5243455B2 (ja) | 2007-02-23 | 2013-07-24 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 新規化合物 |
JP5736098B2 (ja) | 2007-08-21 | 2015-06-17 | アッヴィ・インコーポレイテッド | 中枢神経系障害を治療するための医薬組成物 |
US8217038B2 (en) | 2009-10-07 | 2012-07-10 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
-
2012
- 2012-01-13 KR KR1020120004235A patent/KR101332805B1/ko active IP Right Grant
- 2012-03-30 US US14/008,899 patent/US9073906B2/en active Active
- 2012-03-30 CN CN201280017070.7A patent/CN104080766B/zh active Active
- 2012-03-30 EP EP12763010.1A patent/EP2740723B1/en active Active
- 2012-03-30 BR BR112013024828-9A patent/BR112013024828B1/pt active IP Right Grant
- 2012-03-30 WO PCT/KR2012/002407 patent/WO2012134233A2/ko active Application Filing
- 2012-03-30 ES ES12763010.1T patent/ES2633863T3/es active Active
- 2012-03-30 JP JP2014502483A patent/JP5944483B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP2740723A4 (en) | 2015-01-07 |
CN104080766B (zh) | 2017-02-15 |
JP2014517812A (ja) | 2014-07-24 |
WO2012134233A3 (ko) | 2013-01-10 |
ES2633863T3 (es) | 2017-09-25 |
CN104080766A (zh) | 2014-10-01 |
EP2740723B1 (en) | 2017-05-10 |
US9073906B2 (en) | 2015-07-07 |
JP5944483B2 (ja) | 2016-07-05 |
US20140024636A1 (en) | 2014-01-23 |
WO2012134233A2 (ko) | 2012-10-04 |
KR20120111965A (ko) | 2012-10-11 |
EP2740723A2 (en) | 2014-06-11 |
BR112013024828B1 (pt) | 2020-08-04 |
KR101332805B1 (ko) | 2013-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015018738A8 (pt) | compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica | |
BR112015016793A2 (pt) | compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim | |
BR112015019921A2 (pt) | composto inibidor de trk | |
BR112015012197A8 (pt) | usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos | |
BR112014013661A8 (pt) | derivados de nucleosídeos 2,4-difluoro-2-metil substituídos como inibidores de replicação de hcv-rna | |
BR112014025711A8 (pt) | composto, medicamento, e, uso de um composto | |
BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
BR112013010310A2 (pt) | inibidores de acetil-coa carboxilase de lactama n1/n2 | |
BR112014026493A2 (pt) | derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta | |
BR112012012529A2 (pt) | composto indol e seu uso farmacêutico | |
BRPI0710485B8 (pt) | composições líquidas úteis no tratamento de doenças respiratórias | |
GT200800256A (es) | Derivados de pirazolo [3,4-d]-pirimidina útiles para tratar trastornos respiratorios | |
BR112015032921A8 (pt) | compostos de benzofuranila e benzoxazolila substituídos e utilizações dos mesmos | |
BR112014000371A2 (pt) | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença | |
BR112012020311A2 (pt) | "compostos, medicamento, método para inibir um ciclo de divisão celular, método para a profilaxia ou tratamento de câncer, e, uso do composto." | |
BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
EA201500265A1 (ru) | Ингибиторы репликации вирусов гриппа | |
BR112012021364A2 (pt) | "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas". | |
BR112014015845A8 (pt) | derivados de azetidina, composições farmacêuticas e seu uso | |
BRPI0913291A2 (pt) | composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto | |
BR112015018491A2 (pt) | triterpenoides c-19-modificados com atividade inibidora de maturação de hiv | |
BR112012032087A2 (pt) | composto, medicamento, e, uso de um composto | |
BR112012031580A2 (pt) | derivado de tetra-hidrocarbolina | |
BR112017003186A2 (pt) | composição farmacêutica para tratamento de cancer positivo para mutação em flt3, inibidor de flt3 mutante e usos dos mesmos | |
BR112015017251A8 (pt) | composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/03/2012, OBSERVADAS AS CONDICOES LEGAIS. |